- Karolinska Development’s portfolio company Umecrine Cognition initiates second part of clinical phase 1a/2 study in PBC
- Karolinska Developments portföljbolag Umecrine Cognition inleder andra delen av bolagets fas 1b/2-studie i PBC
- Delårsrapport för januari – mars 2024
- Interim Report - January-March 2024
- Aktieägarna i Karolinska Development AB (publ) kallas till årsstämma
- Notice of Annual General Meeting in Karolinska Development AB (publ)
- Karolinska Development’s portfolio company Umecrine Cognition presents positive safety data from the first part of its Phase 1b/2 study in PBC
- Karolinska Developments portföljbolag Umecrine Cognition presenterar positiva säkerhetsdata från första delen av bolagets fas 1b/2-studie i PBC
- Karolinska Developments årsredovisning för 2023 har publicerats
- Karolinska Development Annual Report 2023 published
More ▼
Key statistics
On Monday, Karolinska Development AB (KDEV:STO) closed at 1.64, 16.45% above the 52 week low of 1.41 set on Oct 30, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.62 |
---|---|
High | 1.70 |
Low | 1.58 |
Bid | 1.62 |
Offer | 1.64 |
Previous close | 1.62 |
Average volume | 122.92k |
---|---|
Shares outstanding | 267.52m |
Free float | 94.80m |
P/E (TTM) | 13.01 |
Market cap | 433.39m SEK |
EPS (TTM) | 0.1245 SEK |
Data delayed at least 15 minutes, as of May 13 2024 17:00 BST.
More ▼